Xenetic Biosciences Appoints New CMO & CSO, CMO Departs

TL;DR

Xenetic Biosciences shakes up leadership: new CMO/CSO in, old CMO out.

AI Summary

On May 16, 2024, Xenetic Biosciences, Inc. announced the appointment of Dr. Jeffrey M. Hackman as Chief Medical Officer and Dr. David M. Goldenberg as Chief Scientific Officer. The company also disclosed the resignation of Dr. Craig M. Fraser from his role as Chief Medical Officer, effective May 15, 2024. These changes are part of the company's ongoing strategic initiatives.

Why It Matters

Key leadership changes in medical and scientific roles can signal shifts in the company's research and development strategy and future product pipeline.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially in scientific and medical roles, can introduce uncertainty regarding the company's strategic direction and execution.

Key Players & Entities

• Xenetic Biosciences, Inc. (company) — Registrant
• Dr. Jeffrey M. Hackman (person) — Appointed Chief Medical Officer
• Dr. David M. Goldenberg (person) — Appointed Chief Scientific Officer
• Dr. Craig M. Fraser (person) — Resigned Chief Medical Officer
• May 16, 2024 (date) — Date of Report
• May 15, 2024 (date) — Effective date of Dr. Fraser's resignation

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share XBIO The Nasdaq

Filing Documents

• xenetic_8k.htm (8-K) — 32KB
• xenetic_ex9901.htm (EX-99.1) — 13KB
• image_001.gif (GRAPHIC) — 5KB
• 0001683168-24-003779.txt ( ) — 268KB
• xbio-20240516.xsd (EX-101.SCH) — 4KB
• xbio-20240516_def.xml (EX-101.DEF) — 26KB
• xbio-20240516_lab.xml (EX-101.LAB) — 36KB
• xbio-20240516_pre.xml (EX-101.PRE) — 25KB
• xenetic_8k_htm.xml (XML) — 5KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 16, 2024, the Board of Directors (the "Board") of Xenetic Biosciences, Inc. (the "Company") appointed James F. Parslow, the Company's Chief Financial Officer, to the position of Interim Chief Executive Officer. Mr. Parslow will continue to serve as the Company's principal financial officer. Mr. Parslow, 59, has served as the Company's Chief Financial Officer since April 2017. Mr. Parslow previously served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc., a publicly-traded business-to-business e-commerce company brokering energy and environmental commodities, from 2006 until its acquisition in 2015. Mr. Parslow is a Certified Public Accountant with over 35 years of experience serving private and public companies in the biotech, e-commerce, and clean tech industries. He holds an A.B. in Economics and Accounting from the College of the Holy Cross and an M.B.A. with a concentration in Finance from Bentley University. There is no arrangement or understanding between Mr. Parslow and any other person pursuant to which he was appointed as Interim Chief Executive Officer of the Company. Furthermore, there are no (i) family relationships between Mr. Parslow and any director or other executive officer of the Company, or with any person selected or nominated to become an executive officer or a director of the Company or (ii) related party transactions with Mr. Parslow requiring disclosure pursuant to Item 404(a) of Regulation S-K. On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately, and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable. In addition on May 16, 2024, the Company and Dr. C

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On May 22, 2024, the Company issued a press release announcing the appointment of James F. Parslow as the interim Chief Executive Officer of the Company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated May 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENETIC BIOSCIENCES, INC. By: /s/ James Parslow Date: May 22, 2024 Name: James Parslow Title: Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR